Hyperfine, Inc.

HYPR ·Healthcare, Medical Devices, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Operating Activities
Net Income $-35.6M $-40.7M $-44.2M $-44.2M $-64.9M $-23.4M
Depreciation & Amortization — — — $1.0M $726.0K $289.0K
Depreciation $1.1M $1.0M $1.1M $1.0M $726.0K —
Amortization — — — — — —
Stock-Based Compensation $2.8M $4.4M $4.7M $10.7M $6.9M $1.1M
Net Cash from Operating Activities $-27.9M $-38.8M $-41.8M $-72.3M $-47.2M $-21.5M
Investing Activities
Capital Expenditures $1.2M $383.0K $804.0K $585.0K $2.7M $1.6M
Business Acquisitions — — — — — —
Net Cash from Investing Activities $-1.2M $-383.0K $-804.0K $-585.0K $-2.7M $-1.6M
Financing Activities
Dividends Paid — — — — — —
Stock Repurchases — — — — — —
Net Cash from Financing Activities $27.5M $1.0M $174.0K $7.0K $176.8M $60.9M
Net Change in Cash — — — — — —
Free Cash Flow $-29.1M $-39.2M $-42.6M $-72.9M $-49.9M $-23.1M